USP and Public Policy
Left
Refine Your Search
USP appreciates the opportunity to submit comments on the horizontal approaches to food standards of identity (SOI) modernization. These comments are being submitted on behalf of the Food Science…
Learn More
USP appreciates this opportunity to discuss modernizing Standards of Identity (SOI) and the use of a horizontal approach to modernization.
Learn More
USP appreciates the opportunity to comment on “The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Insulin Biosimilar and Interchangeable Products”.
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA or the Agency) final guidance, “Standards Development and the Use of Standards in Regulatory Submissions Reviewed…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA) draft guidance, “Nonproprietary Naming of Biological Products: Update.”
Learn More
USP supported the Food and Drug Administration's (FDA's) announcement that it will modernize policies to help ensure the availability of safe, well-manufactured, and appropriately labeled…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA) draft guidance, “Nonproprietary Naming of Biological Products: Update.”
Learn More
USP appreciates the opportunity to comment on the above referenced FDA Request for Comments on Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds.
Learn More
USP appreciates the opportunity to provide written comments in addition to the oral testimony USP gave on September 04, 2018, during the public hearing on competition and innovation in the biological…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) draft guidance: Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management.
Learn More